Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mobile-Compatible AI-Powered System to Revolutionize Malaria Diagnosis

By LabMedica International staff writers
Posted on 04 Sep 2025

Malaria remains a major health burden in Malaysia, with Plasmodium knowlesi now the leading cause of human cases. More...

Its rapid replication cycle and similarities to other malaria species make timely and accurate diagnosis particularly difficult. In rural clinics, trained parasitologists are scarce, and misidentification is common. To address these gaps, researchers have developed a locally tailored artificial intelligence (AI) system that enhances the accuracy and speed of malaria diagnosis.

The new system, called MalariaCare+, was created by a team at Universiti Malaya (UM, Kuala Lumpur, Malaysia) and uses a graph-enhanced YOLO deep learning model to detect infected red blood cells, even on overlapping or low-quality slides. MalariaCare+ is being tested in collaboration with Universiti Malaysia Sarawak (UNIMAS, Sarawak, Malaysia) and has been integrated into an app tested with blood samples.

Designed for local realities, it is mobile-compatible and acts as a diagnostic assistant rather than a replacement for medical professionals. Early results show the AI providing healthcare workers with reliable “second set of expert eyes,” improving diagnostic accuracy in real-world rural conditions. The system’s design, shaped by input from doctors, technicians, and field researchers, ensures responsiveness to the on-the-ground challenges of malaria detection in Malaysia.

Next steps include adding a stage-specific classifier to identify Plasmodium knowlesi life stages, enabling faster treatment decisions. Planned updates will bring real-time analysis, visual explanations of AI findings, and secure patient history tracking that works even in low-connectivity areas. In addition to diagnosis, MalariaCare+ will be integrated into public health training at UM and UNIMAS, equipping future healthcare workers with both biological and technological expertise.

“This isn’t AI for the sake of it. This is applied intelligence; built with and for the people who deal with malaria on the ground,” said Associate Professor Dr. Khairunnisa Hasikin, project lead at Universiti Malaya. “We trained the AI to see what even the sharpest eyes might miss. It’s not about replacing doctors and clinicians. It’s about giving them a second set of expert eyes when they need it most.”

Related Links:
Universiti Malaya
UNIMAS


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.